Details for Patent: 12,194,022

« Back to Dashboard

Which drugs does patent 12,194,022 protect, and when does it expire?

Patent 12,194,022 protects BARHEMSYS and is included in one NDA.

This patent has fifty-four patent family members in twenty-six countries.

Summary for Patent: 12,194,022

Title:	Use of amisulpride as an anti-emetic
Abstract:	Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
Inventor(s):	Julian Clive Gilbert, Robert William Gristwood, Nicola Cooper, Gabriel Fox
Assignee:	Acacia Pharma Ltd
Application Number:	US18/095,612
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,194,022
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 12,194,022

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Lxo Ireland	BARHEMSYS	amisulpride	SOLUTION;INTRAVENOUS	209510-001	Feb 26, 2020		RX	Yes	Yes	12,194,022					PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
Lxo Ireland	BARHEMSYS	amisulpride	SOLUTION;INTRAVENOUS	209510-001	Feb 26, 2020		RX	Yes	Yes	12,194,022					PREVENTION AND TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING
Lxo Ireland	BARHEMSYS	amisulpride	SOLUTION;INTRAVENOUS	209510-002	Sep 1, 2020		RX	Yes	Yes	12,194,022					PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING
Lxo Ireland	BARHEMSYS	amisulpride	SOLUTION;INTRAVENOUS	209510-002	Sep 1, 2020		RX	Yes	Yes	12,194,022					PREVENTION AND TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING

International Family Members for US Patent 12,194,022

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011225898
Brazil	112012022746
Canada	2792392
China	102892407